Australia's most trusted
source of pharma news
Sunday, 13 April 2025
Posted 25 August 2017
Novotech, Australia's largest independent clinical research organisation (CRO), has been acquired by US private equity company TPG Capital for a reputed $300 million.
TPG announced it had "signed a binding agreement to acquire Novotech from Mercury Capital and Novotech founder, Alek Safarian" in a move it said would help it "achieve its growth ambitions".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.